Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay

Clinica Chimica Acta

Volumn 338, Issue 1-2, 2003, Pages 107-115

  Yeo, Kiang Teck J ^a   Wu, Alan H B ^b   Apple, Fred S ^c   Kroll, Martin H ^d   Christenson, Robert H ^e   Lewandrowski, Kent B ^f   Sedor, Frank A ^g   Butch, Anthony W ^h  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UCLA MEDICAL CENTER   (United States)

Author keywords

BNP; Brain natriuretic peptides; Cardiac markers; Congestive heart failure; NT proBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; ARTICLE; BIOSITE TRIAGE BNP ASSAY; BLOOD SAMPLING; CONTROLLED STUDY; EVALUATION; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN DETERMINATION; ROCHE NT PROBNP ASSAY; ROOM TEMPERATURE;

EID: 0344586166     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.08.016     Document Type: Article

References (28)

1. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81.
2. Hosoda K., Nakao K., Mukoyama M., Saito Y., Jougasaki M., Shirakami G.et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension. 17:1991;1152-1155.
3. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
4. Hunt P., Richards A., Nicholls M., Yandle T., Doughty R., Espiner E. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin. Endocrinol. 47:1997;287-296.
5. Mair J., Friedl W., Thomas S., Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand. J. Clin. Lab. Invest. 59:1999;132-142.
6. Yoshimura M., Yasue H., Okumura K., Ogawa H., Jougasaki M., Mukoyama M. et al. Cardiac failure: different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 87:1993;464-469.
7. Omland T., Asbjorn A., Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart. 76:1996;232-237.
8. McDonagh T., Robb S., Murdoch D., Morton J., Ford I., Morrison C.et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:1998;9-13.
9. Dao Q., Krishnaswamy P., Kazanegra R., Harrison A., Amirnovin R., Lenert L.et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37:2001;379-385.
10. Maisel A., Krishnaswamy P., Nowak R., McCord J., Hollander J., Duc P.et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347:2002;161-167.
11. Morrison L., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol. 39:2002;202-209.
12. Arakawa N., Nakamura M., Hidehiko A., Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J. Am. Coll. Cardiol. 27:1996;1656-1661.
13. Omland T., Asbjorn A., Bonarjee V., Caidahl K., Lie R., Nilsen D.et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 93:1996;1963-1969.
14. De Lemos J., Morrow D., JH B., Omland T., Sabatine M., McCabe C.et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345:2001;1014-1021.
15. Morrow D., de Lemos J., Sabatine M., Murphy S., Demopoulos L., DiBattiste P.et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J. Am. Coll. Cardiol. 41:2003;1264-1272.
16. Toth M., Vuorinen K.H., Vuolteenaho O., Hassinen I.E., Uusimaa P.A., Leppaluoto J.et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am. J. Physiol. 266:1994;H1572-H1580.
17. Goetze J.P., Christoffersen C., Perko M., Arendrup H., Rehfeld J.F., Kastrup J.et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 17:2003;1105-1107.
18. Talwar S., Squire I., Davies J., Barnett D., Ng L. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur. Heart J. 20:1999;1736-1744.
19. Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin. Chim. Acta. 310:2001;193-197.
20. Masson S., Vago T., Baldi G., Salio M., De Angelis N., Nicolis E.et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin. Chem. Lab. Med. 40:2002;761-763.
21. Richards A., Nicholls M., Yandle T., Frampton C., Espiner E., Turner J. et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:1998;1921-1929.
22. Jernberg T., Stridsberg M., Venge P., Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no S-T elevation. J. Am. Coll. Cardiol. 40:2002;437-445.
23. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Herlitz J.et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 106:2002;2913-2918.
24. Yeo K., Siegel A., Wong K., Lavalley K., Pearlman J., Foote R. Detection of exercise-induced ischemia by measurement of NT-proBNP. Clin. Chem. 49:2003;A67.
25. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:2000;1126-1130.
26. Smith A., Wu A. Analytical performance evaluation of the Bayer Advia Centaur BNP immunoassay. Clin. Chem. 49:2003;A71.
27. Roche Diagnostics ProBNP technical bulletin for Elecsys systems 2003.
28. McCullough P., Nowak R., McCord J., Hollander J., Herrmann H., Steg P.et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation. 106:2002;416-422.